Decorin Gene Expression Analysis for S-1 Chemotherapy Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the administration effect of the anticancer drug S-1, which combines tegafur, gimeracil, and oteracil potassium, are time-consuming and complex, leading to variable results and potential side effects due to resistance issues in cancer chemotherapy.
Innovation Solution
Measuring the expression level of the decorin (DCN) gene in biological samples from cancer patients to predict sensitivity or resistance to S-1, allowing for a quick and accurate determination of chemotherapy effectiveness before administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell culture technology is used to determine chemotherapy sensitivity, then measurement precision is improved, but device complexity and time consumption increase
Solution Approach 1:
The invention extracts the essential diagnostic function from complex cell culture techniques by identifying and measuring specific gene expression patterns (DCN, EGFR, and other markers) that directly indicate chemotherapy sensitivity. This extraction transforms a complex multi-day cell culture process into a simplified gene expression measurement that can be performed on tissue samples without requiring active cell cultivation.
Solution Approach 2:
The invention replaces the mechanical cell culture system with a biochemical gene expression analysis system. Instead of physically culturing cells and observing their response to drugs, the method uses molecular biology techniques (RT-PCR, immunohistochemistry, or in situ hybridization) to detect gene expression patterns that predict cellular response, thereby substituting a complex mechanical biological system with a more controllable biochemical assay.
2Measurement precision
If cell culture technology is used to determine chemotherapy sensitivity, then measurement precision is improved, but loss of time increases
Solution Approach 1:
The invention performs preliminary analysis by measuring gene expression patterns in the original tissue sample before chemotherapy administration begins. By assessing the expression levels of DCN, EGFR, and other predictive markers in advance, the method determines chemotherapy sensitivity without requiring actual cell culture exposure time, thereby providing preliminary diagnostic information that guides treatment selection before therapy starts.
Solution Approach 2:
The invention creates a molecular copy of the cellular response state by measuring gene expression patterns that reflect how cells would respond to chemotherapy. Instead of physically exposing cells to drugs and observing growth inhibition, the method detects molecular signatures (gene expression profiles) that copy or represent the expected cellular response, providing diagnostic information without the time cost of actual drug exposure and cell culture.
3Productivity
If gene expression measurement is used to determine S-1 sensitivity, then productivity is improved, but measurement precision may worsen
Solution Approach 1:
The invention segments the complex problem of chemotherapy sensitivity determination into multiple measurable gene expression components. Instead of relying on a single marker, the method evaluates expression levels of DCN, EGFR, and other specific genes independently, then integrates these segmented measurements to comprehensively assess sensitivity. This segmentation allows parallel processing of multiple diagnostic parameters, improving productivity while maintaining precision through multi-parameter validation.
Solution Approach 2:
The invention creates a universal diagnostic platform that can measure multiple gene expression markers (DCN, EGFR, and others) using the same technical methodology. This multi-functional approach allows a single measurement system to evaluate various aspects of chemotherapy sensitivity simultaneously, improving productivity by eliminating the need for separate assays while maintaining measurement precision through consistent methodology across all markers.
Data Source
AI summary
Provided is a method of determining a therapeutic effect of cancer chemotherapy with an anticancer drug obtained by blending three ingredients, i.e., tegafur, gimeracil, and oteracil potassium as active ingredients (hereinafter abbreviated as S-1) quickly, simply, and accurately before carrying out the cancer chemotherapy. Specifically, provided is a method of determining an administration effect in chemotherapy with S-1, the method comprising: a step (a) of measuring expression level of a decorin gene in a biological sample collected from a subject to be diagnosed; and a step (b) of determining an administration effect of S-1 based on the expression level of the gene obtained from the measurement.